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ABSTRACT
RIG-I is a cytosolic receptor for non-self RNA that
mediates immune responses against viral infections
through IFNa/b production. In an attempt to identify
novel tools that modulate IFNa/b production, we
used SELEX technology to screen RNA aptamers
that specifically target RIG-I protein. Most of the
selected RIG-I aptamers contained polyU motifs in
the second half regions that played critical roles in
the activation of RIG-I-mediated IFNb production.
Unlike other known ligands, RIG-I aptamer bound
and activated RIG-I in a 50-triphosphate-
independent manner. The helicase and RD domain
of RIG-I were used for aptamer binding, but intact
RIG-I protein was required to exert aptamer-
mediated signaling activation. Furthermore, replica-
tion of NDV, VSV and influenza virus in infected host
cells was efficiently blocked by pre- or post-
treatment with RIG-I aptamer. Based on these
data, we propose that RIG-I aptamer has strong po-
tential to be an antiviral agent that specifically
boosts the RIG-I-dependent signaling cascade.
INTRODUCTION
Infection by both known and newly emerging RNA
viruses, such as hepatitis C virus (HCV), Ebola virus,
inﬂuenza virus and SARS-CoV, are a severe threat to
public health. RNA viruses cause injury to the infected
organs and disrupt normal functioning, leading to high
levels of morbidity and mortality (1–3). RNA viruses
exhibit genomic hyper-variation, mainly caused by low
ﬁdelity of the virus-derived RNA-dependent RNA poly-
merase activity (4,5). Instability of the RNA viral genome
allows viruses to escape from virus-speciﬁc drugs and
vaccines. Because the development of stable vaccines for
RNA viruses is a challenging task, alternative tools that
modulate the immune response against a viral infection
are of great interest (6–8). Among them, IFN-based
therapy shows a strong potential for HCV clearance by
stimulation of the innate and adaptive immune system of
the infected host, although IFN resistance is often
reported in HCV-infected patients. The concept of IFN-
based therapy for virus eradication prompted the explor-
ation of therapeutic agents that target innate immune
systems of the infected host (9). In this regard, synthetic
agonists for Toll-like receptors (TLR) have been success-
fully developed as potent IFN-inducers, and their poten-
tial to control viral replication and infection-related
diseases has been extensively studied (6,8,10).
Early detection of the virus in the infected host relies on
speciﬁc receptors that recognize virus-derived molecular
patterns, such as double stranded RNA (dsRNA) or
50-triphosphate-single stranded RNA (ssRNA) (11).
TLR3, TLR7, TLR8 and TLR9 localize in the
membrane of the endosomal compartment and sense
non-self molecular patterns that are derived from the
viral particles. In contrast, retinoic acid-inducible genes I
(RIG-I) and melanoma differentiation-associated gene
ﬁve (MDA-5) detect molecular patterns derived from
replicating RNA viruses in the cytoplasm (12). Upon rec-
ognition of the intracellular non-self RNA, both RIG-I
and MDA5 proteins are recruited to the mitochondria,
via association with Cardif (also called IPS-1, VISA or
MAVS), and trigger IFNb production and signaling
through the activation of IRF3 and NFkB (13).
Although RIG-I and MDA5 utilize the same signaling
pathways for IFNb production, they exhibit differential
preferences toward RNA substrates, and therefore detect
different types of viruses. It has been suggested that an
RNA structure with a 50-triphosphate moiety can be
found during the replication of ssRNA viruses, such as
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ial virus (RSV) and inﬂuenza virus, and that this structure
is selectively recognized by RIG-I (14–17). Meanwhile,
MDA5 preferentially detects long stretches of dsRNA
structures, which are mainly produced by replicating
Encephalomyocarditis virus (EMCV) or Reovirus
(16,18,19). The signiﬁcance of viral recognition and sig-
naling cascades mediated by cytosolic RIG-I and MDA5
was well demonstrated in vivo using RIG-I or MDA5
knockout mice. RIG-I /  mice exhibit defects in the
immune response against NDV, Sendai virus (SeV) and
vesicular stomatitis virus (VSV) infection, whereas
MDA5 /  mice exhibit speciﬁc defects against EMCV
infection (20).
Aptamers are single-stranded nucleic acid molecules
that are selected with SELEX (systematic evolution of
ligands by exponential enrichment) technology based on
their afﬁnities and speciﬁcities to target proteins (21,22).
Due to their rapid selection process, high stability and
relatively low immunogenicity, aptamers have become a
favorite choice among molecular detection tools, replacing
the use of antibodies (23). Furthermore, depending on the
modes of action, aptamers are capable of modulating
activities of target molecules, which facilitates the devel-
opment of aptamers for therapeutic purposes (24–26).
Most aptamers with anti-viral activity have been de-
veloped against virus-speciﬁc proteins, such as Tat of
HIV or NS3 of HCV, and less effort has focused on
aptamers that target the innate immune response against
viral infection (22,27–29). In an attempt to develop
aptamers that speciﬁcally control RIG-I-mediated
anti-viral responses in the infected host cells, we
screened RNA oligonucleotides speciﬁc for RIG-I using
advanced-SELEX technology.
MATERIALS AND METHODS
Cells, virus and reagents
HepG2 cells were maintained in minimum essential medium
(MEM) containing 10% fetal bovine serum (FBS; Hyclone,
Logan, UT, USA) and penicillin-streptomycin (Gibco).
Huh7 cells and A549 cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) with 10% FBS and anti-
biotics. NDV-GFP, VSV-GFP and Inﬂuenza A (PR8
strain)-GFP were kindly provided by Dr Peter Palese
(Mount Sinai School of Medicine, USA) and by Dr
Adolfo Garcia-Sastre (Mount Sinai School of Medicine,
USA), respectively. For transfection of DNA plasmids and
RNA oligonucleotides including aptamers, Lipofectamine
2000 (Invitrogen) was used. IFNb and polyI:C were
purchased from R&D Systems and Amersham Biosciences,
respectively. For synthetic 50-triphosphate-dsRNA, both
3P-G and AS G24 were separately synthesized and
annealed, following the method as described (30). For
secreted TNFa and RANTES, human TNFa/TNFSF1A
ELISA Development kit (R&D System) and human
RANTES ELISA kit (Thermo scientiﬁc) was used,
respectively.
Plasmids
The pIRES-Luc (Stratagene) and pNFkB-Luc (Stratagene)
plasmids were purchased, and the pPRD-III-I-Luc plasmid
was provided by Dr Katherine A. Fitzgerald (University of
Massachusetts). pEF-BOS-Flag-RIG-I was provided by
Dr Takashi Fujita (Institute for Virus Research, Kyoto
University). The construction of pEF-BOS-Flag-
Helicase+RD and pEF-BOS-Flag-CARD plasmids was
described previously (31). pEF-BOS-Flag-RD was sub-
cloned using following primers: 50-GCTCTAGATAAGC
CACCATGGAT-30,5 0-CCATCGA TTCATCTTGCTCT
TGCTCTTCCTCTGCC-30. pcDNA3-Flag-MAVS was
kindly provided by Dr Zhijian J. Chen (University of
Texas Southwestern Medical Center), and was subse-
quently sub-cloned into the XhoI/XbaI site of pCS2+MT
plasmid.
Expression and puriﬁcation of human RIG-I protein
A DNA fragment encoding human RIG-I (1–925 amino
acids) was sub cloned into an expression vector derived
from the pFastBac plasmid (Invitrogen). The vector was
designed to express RIG-I as a fusion protein containing
(His)10-glutathion-S-transferase (GST) at the N-terminus.
Recombinant protein was produced in the Sf9 insect cells
based on the Baculovirus expression vector system.
Harvested cells were resuspended and lysed by sonication
in lysis buffer consisting of 50mM Tris (pH 7.5), 100mM
NaCl and 1mM dithiothreitol. The supernatant of cell
lysates was loaded onto a column packed with GST
binding resin (Novagen) and eluted with the same buffer
containing 10mM reduced glutathione. To purify
Flag-RIG-I, Flag-Helicase+RD (218–925 amino acids)
and Flag-CARD (1–217 amino acids) proteins from the
BL21(DE3)-pLsys (Novagen) bacteria, human RIG-I
gene was sub cloned into an expression vector derived
from the pProEX HTa (Invitrogen) or pET-22b CPD
plasmid. The bacteria cells were cultured in LB broth
and induced for over-night at 18 C with 100mM IPTG,
and cells were resuspended and lysed by sonication in lysis
buffer consisting of 50mM Tris (pH 7.5), 1M NaCl and 4
mM b-mercaptoethanol. The supernatant was loaded
onto a column packed with Cobalt resin (Novagen) and
eluted with 20mM Tris (pH 7.5), 200mM NaCl, 4mM
b-mercaptoethanol and 150mM Imidazole. The (His)10-
GST-tag and CPD-(His)10-tag were cleaved by TEV
protease or phytate, and then removed from RIG-I,
Helicase+RD, and CARD by using Cobalt resine.
Subsequently, HiTrap Q and HiLoad 26/60 Superdex
200 columns (GE Healthcare) were used for further
puriﬁcation of proteins. The following primers
were used for cloning of RIG-I and their mutants:
Flag-RIG-I, 50-GAAGGCCTAATGGACTACAAAGACG
-30 and 50-CCGCTCGAGTCATTTGGACATTT CTGC-3’;
Flag-Helicase+RD, 50-CGGCATATGGACTACAAA
GACG-30 and 50-CCGGTC GACTTTGGACATTTCTGC
TGG-30;F l a g - C A R D ,5 0-CGGCATATGGATTATAAG
GAT GAT-30 and 50-CCGGTCGACTGGATCTTCTTGG
TAG-30.
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A synthetic DNA library pool of 50-GCGCAAGCGTGC
TGGGCC-(N40)-CATAACCC AGAGGTCGAT-30 was
ampliﬁed by PCR using the following primers: 50-GGTA
ATACG ACTCACTATAGGGAGAGCGCAAGCGTG
CTGGG-30;5 0-GGGGGGATCCATCGACCT CTGGG
TTATG-30. To prepare RNA oligonucleotides, the PCR
product was in vitro transcribed using a Durascribe T7
Transcription Kit containing 20-F-UTP and 20-F-CTP
(Epicentre Biotechnologies) at 37 C for 3h, followed by
puriﬁcation with G25-sephadex column. At the ﬁrst
SELEX cycle, 1nmol of the RNA oligonucleotide pool
was incubated with 200pmol of biotinylated human
RIG-I protein for 30min in 1  PBS (with 1mM
MgCl2). Oligonucleotide bound to RIG-I was harvested
using biotin-streptavidin system (Sigma), reverse
transcribed and then PCR ampliﬁed. Concentration of
the RNA oligonucleotide pool and RIG-I protein were
gradually reduced at the next round of aptamer selection.
After 13 cycles of SELEX, sequences of the selected clones
were analyzed using automated DNA sequencing. To
remove the 50-triphosphate, 20mgo fin vitro-transcribed
RNA transcripts was incubated with 30U of alkaline
phosphate (NEB) and 40U of RNase inhibitor
(Promega) at 37 C for 1h (14).
Luciferase assay
Cells were transfected with pPRD-III-I-, pISRE-, or
pNKkB-Luc together with pRL-CMV for 36h. For stimu-
lation, cells were transfected with cognate ligands by
Lipofectamine 2000. Using a dual-luciferase assay kit
(Promega), ﬁreﬂy luciferase activity was measured and
normalized with the value of renilla activity, and the
‘Rel. activity (fold)’ relative to the mock-treated sample
was used.
Real-time RT-PCR
Total RNA (1mg) was reverse transcribed using the
Improm-II reverse transcription system (Promega). To
detect NDV-GFP and VSV-GFP, random oligomers
were used for reverse transcription. For PCR, SYBR
premix Ex-Taq (Takara) was used and the Ct values
were obtained using One-step
TM Real-time PCR system
(Applied Biosystem). Data were normalized against
b-actin. The following primers were used: IFNb,5 0-TGC
TCT CCTGTTGTGCTTCTCC-30 and 50-CATCTCATA
GATGGTCAATGCGG-30; RANTES, 50-ATGAAGGT
CTCCAAAGAG-30 and 50-GCTCATCTCCAAAGAG
-30; TNFa,5 0-CACCATCAGCCGCATC-30 and 50-CAG
GGCAATGATCCCA-30; GFP, 50-TTGATGGCAGGC
CTCTTGC-30 and 50-GGAGGATGTTGGACGCAT
T-30; b-actin, 50-TCATGAAGTGTGACGTTGACATC
CGT-30 and 50-CCTAGAAGCATTTGCGGTGCA CG
ATG-30.
RNA interference
Cells were transfected with the appropriate siRNA using
Lipofectamine 2000. The following sequences were used:
siControl, 50-GAAUUUGCACGAAAACGCC-30;s i R I G - I ,
50-GAG GUGCAGUAUAUUCAGG-30; siMDA5,
Qiagen validated siRNA (S103649037). siControl and
siRIG-I were synthesized by the custom design service of
Qiagen.
Western blotting and immunoﬂuorescence staining
For western blot analysis, antibodies against GFP
(Santacruz), RIG-I (ALEXIS Biochemicals), MDA5
(ProSci Incorporated), Flag (M2, Sigma), c-Myc
(Roche), GAPDH (Chemicon) and b-actin (Santacruz)
were used. Immunoreactive signals were developed using
a LAS4000 luminescent image analyzer (Fujiﬁlm). To
detect intracellular localization of IRF3, cells on
coverglass were stimulated with polyI:C (1.5mg/ml) or
aptamers (75pmol) for 4h, ﬁxed with 4%
paraformaldehyde, and then permeabilized in 0.2%
TritonX-100 solution. Cells were incubated with
anti-IRF3 antibody (Santacruz) in 1  PBS containing
0.05% Tween20 at room temperature for 2h. Cells were
then incubated with anti-Rabbit IgG conjugated with
Alexa Fluor 488 (Invitrogen) and Hoechst 33258
(Sigma). Slides were mounted and then analyzed using
an Olympus ﬂuorescence microscope.
In vitro binding assay
For radioactive-labeled aptamer production, aptamers
were in vitro transcribed using Durascribe T7
Transcription Kit with the mixture of 25mM a
32P-GTP
and 2.5mM GTP at 37 C for 3 hours. For end-labeling,
500 pmole of AP-treated aptamer was incubated with T4
polynucleotide kinase (20U, New England Biolabs,
Beverly, MA, USA) and 100pmol of g-
32P-ATP for
30min. The labeled aptamers were subsequently puriﬁed
with CHROMA spin30 column (Clontech). For binding
assay, recombinant protein (10mg) or total lysate (1mg)
from HEK293 cell was incubated with 400pmol of the
labeled aptamer, 2mg of Flag antibody and Protein G
plus/Protein A-Agarose bead (Calbiochem) at 4 C for 1
hour. The
32P-labeled-aptamers bound to RIG-I fraction
was quantitated using liquid scintillation analyzer (LSA).
RESULTS
In vitro selection of RNA aptamers against RIG-I
We screened RIG-I aptamers from a library pool of
 1 10
14 random RNA oligonucleotides using a
puriﬁed full-length human RIG-I protein (Figure 1A).
RNA oligonucleotides bound to RIG-I were harvested,
reverse transcribed and PCR ampliﬁed and then
transcribed in vitro to generate RNA olibonucleotide
pools for the next round of selection (Supplementary
Figure S1). After 13 cycles of selection and ampliﬁcation,
45 independent clones of RIG-I aptamers with unique se-
quences were obtained. Sequence analysis of the 45 clones
indicated that the sequences of the selected RIG-I
aptamers contained high U content (average 51.9%),
with a repeated polyUn motif in the second half of the
sequence (Figure 1B). Among individual aptamer clones,
lengths of the repeated polyUn varied between n=2 to
2726 Nucleic Acids Research, 2012,Vol.40, No. 6n=11 (Figure 1C). We chose eight independent RIG-I
aptamer clones at random and examined for their
in vitro binding afﬁnity to puriﬁed RIG-I protein. For
this purpose, individual RIG-I aptamers were end-labeled
with
32P and were incubated with puriﬁed full-length
RIG-I proteins in the absence or presence of tRNA as a
competitor of non-speciﬁc binding (Figure 1C). Despite
differences in their binding potentials, all of the tested
RIG-I aptamers exhibited strong RIG-I binding ability
compared to the control RNA (library). We attempted
to measure in vitro binding afﬁnity of the selected
aptamers by estimating bound and free forms of labeled
aptamer under equilibrium conditions using different
amounts of RIG-I protein. For this purpose, we picked
CL9, which showed relatively weak binding compared to
the other clones, hence provides lower bound value of the
selected aptamer. In vitro Bmax and Kd value of CL9 were
0.29fmol/mg and 37.2nM, respectively (Supplementary
Figure S2).
RNA aptamers were prepared in vitro using T7 RNA
polymerase, and as a result, the 50-triphosphate moiety in
the ﬁrst nucleotide position remained (32). Because the
50-triphosphate moiety in ssRNA is known to be
recognized by RIG-I (33,34), it is possible that the
50-triphosphate in the RNA aptamer directly acts as a
ligand for RIG-I protein. To test this possibility, the
in vitro binding afﬁnity of native and alkaline phosphatase
(AP)-treated aptamers to RIG-I were directly compared
(Figure 1D). For every aptamer tested, the binding of
aptamers to RIG-I protein was not signiﬁcantly altered
by the presence of the 50-triphosphate moiety, indicating
that the selected aptamer sequences governs speciﬁc
binding to RIG-I protein.
Stimulation of the RIG-I-dependent IFNb production by
RIG-I RNA aptamers
To determine whether the RIG-I aptamers were able to
modulate RIG-I-mediated IFNb production, we
stimulated HepG2 cells with native or AP-treated RNA
aptamers and measured IFNb promoter activity using the
PRD-III-I-Luc reporter (35). HepG2 cells express a fair
amount of endogenous RIG-I protein and are therefore
suitable for testing the regulatory effects of RIG-I
aptamers (36,37). Every tested aptamer elicited stimula-
tory effects on the IFNb promoter (PRDIII-I)
(Figure 2A), and there were no signiﬁcant differences
between native and AP-treated aptamers, except for
CL11. Efﬁcacy of 50-triphosphate removal by AP was sep-
arately tested using chemically synthesized dsRNA with
50-triphosphate (Figure 2B). Reporter activity induced by
50-triphosphate-dsRNA has been signiﬁcantly reduced by
AP treatment, indicating that AP efﬁciently removes the
50-triphosphate moiety. To examine whether the regula-
tory effect of the screened aptamers depends RIG-I
for their function, cells were transfected with RIG-I or
MDA5 siRNA before aptamer treatment. The ability of
RIG-I aptamer, CL9, to stimulate the IFNb-driven
promoter activity was signiﬁcantly impaired when
RIG-I, but not MDA5, expression was reduced
(Figure 2C). Functional knock-down of MDA5 was sep-
arately conﬁrmed in the polyI:C stimulated cells
(Supplementary Figure S3). Signaling activity of the
RIG-I aptamer was then compared to those of the con-
ventional ligands of RIG-I, 50-triphosphate-dsRNA or
polyI:C (Figure 2D). Stimulating cells with
50-triphosphate-dsRNA induced IFNb promoter activity,
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Figure 1. SELEX-based RIG-I aptamer screening. (A) Schematic diagram depicting the RIG-I speciﬁc RNA aptamer screening process. RNA
nucleotides with speciﬁc binding to the puriﬁed human recombinant RIG-I protein were selected with multiple rounds of the binding, washing,
elution, PCR ampliﬁcation, and RNA transcription, starting with the library pool of the RNA oligomers (see ‘Materials and Methods’ section).
(B) Nucleotide usages found in the 45 selected RIG-I RNA aptamers are shown. (C) Left, Sequences of the RIG-I aptamer used in this study. Right,
RNA-EMSA using
32P-labeled RIG-I aptamers and puriﬁed human RIG-I protein. Arrowhead indicates aptamer-RIG-I complex. Asterisk, free
aptamer. (D) The level of
32P-labeled-aptamers (native or AP-treated) bound to RIG-I protein in vitro were quantitated using liquid scintillation
analyzer (LSA). Data represent mean values±standard deviation (±SD), from three independent experiments.
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7 human hepatoma cells. In contrast, CL9 exhibited
moderate levels of the IFNb promoter activity in the
HepG2 and Huh7 cells, and this activity was further
enhanced by RIG-I overexpression (Figure 2D).
Depending on its length, polyI:C was reported to
activate RIG-I and MDA5 differentially: Long (1–10kb)
strands of polyI:C bind to MDA5, while short (<1kb)
strands of polyI:C preferentially activate RIG-I (18).
CL9 exhibited similar levels of signaling activity relative
to long forms of polyI:C, and >10-fold higher activity
than RNaseIII-digested, short form of polyI:C
(Figure 2E and Supplementary Figure S4).
We next examined whether RIG-I aptamer activates
signaling pathways for IFNb production. When
treated, CL9 induced nuclear translocation of IRF3, a
transcription factor that occupies the IFNb promoter
(Figure 3A), and stimulated STAT1-mediated, but not
NFkB-mediated, trans-activation activity (Figure 3B). As
a result, mRNA expression of IFNb, RANTES and TNFa
was dramatically enhanced by CL9 (Figure 3C). Protein
levels of RANTES and TNFa were separately conﬁrmed
in the CL9-stimulated condition (Figure 3D). These
results indicate that RNA aptamers with speciﬁc binding
potential to RIG-I protein stimulate IFNb-mediated sig-
naling pathways in a RIG-I-dependent, yet
50-triphosphate-RNA-independent manner.
PolyU motif of the aptamer CL9 is critical to activate
RIG-I-mediated signaling pathways
To identify the key regulatory feature that is responsible
for RIG-I activation, we constructed various CL9 mutants
and measured their effect on the expression of IFNb
mRNA (Figure 4A). Every RNA oligonucleotide
selected for the RIG-I aptamer harbored common 50 and
30 tails that were used for reverse transcription and amp-
liﬁcation step of SELEX screening (see ‘Materials and
Methods’ section). Therefore we ﬁrst evaluated the contri-
bution of the 50 and 30 common tails. Deletion mutations
in the 30 common tail that ﬂank polyU motif in the CL9
(3ct-1, 3ct-2) did not alter stimulatory effect on IFNb pro-
duction (Figure 4B), while additional deletion of the 50
common tail was deteriorative (Figure 4C). Base substitu-
tions in the predicted stem-loop structure (sl;
Supplementary Figure S5) did not have any effect on the
IFNb expression. In contrast, a long stretch of polyU
motif was critical for its activity to produce IFNb,a s
partial substitution of consecutive ‘U’s to ‘A’s (pU-1,
pU-2) almost completely abolished its activity
(Figure 4B). Furthermore, complete substitution of
polyU motif to poly A, C or G (pA, pC, pG) impaired
its activity to induce IFNb mRNA expression (Figure 4C).
Interestingly, relative position of polyU motif within
aptamer was critical, as ipU mutant which contains
same nucleotide composition but internal polyU motif
induces less IFNb mRNA expression, compare to wt
(Figure 4C). These results clearly indicate that a polyU
motif within aptamer sequence plays critical roles in the
activation of RIG-I-mediated IFNb production.
To investigate whether signaling activity of the selected
aptamer is depends on its binding ability to RIG-I protein,
we then evaluated the binding potential of the mutant
aptamers to the puriﬁed RIG-I protein. In general, signal-
ing activity of the mutant aptamers to produce IFNb posi-
tively correlates with their in vitro RIG-I binding, except
pU-1 and pU-2 mutants (Figure 4D and E). Although
pU-1 and pU-2 mutants fail to activate IFNb production,
both of them exhibited comparable levels of RIG-I
binding. These data suggest that RIG-I aptamer might
not act as a conventional ligand for RIG-I, but function
to stabilize the conformation of RIG-I in an active state.
Finally, we examined the IFNb production activity of
CL9 synthesized with 20-OH-UTP and 20-OH-CTP
(Figure 4F). Signaling activity of CL9 was completely
abolished when conventional nucleotides were used
instead of 20-F-UTP and 20-F-CTP, suggesting that
20-F-containing CL9 has a unique structural feature for
RIG-I activation.
Figure 2. RIG-I aptamers strongly activate RIG-mediated signaling
activity. After transfection with PRD-III-I-Luc and pRL-CMV for
36h, HepG2 or Huh7 cells were stimulated with (A) 75pmol of
RIG-I aptamers, (B) 100pmol of 50-triphosphate-dsRNA for 6h. (C)
Thirty-six hours after transfection with indicated siRNAs, HepG2 cells
were stimulated with AP-treated aptamers (75pmol) for 6h.
Endogenous RIG-I and MDA5 were detected in the same cell lysates
used for luciferase assay. (D) Similar to (A), except that cells were
co-transfected with Empty (pEF-BOS) or RIG-I
(pEF-BOS-Flag-RIG-I) with luciferase vectors, and then stimulated
with 100pmol of indicated activators for 6h. (E) HepG2 cells were
stimulated with equal amounts (1.5mg/ml) of polyI:C,
RNaseIII-treated short polyI:C, AP-treated RNA library, or
AP-treated CL9 for 6h before luciferase assay. Data from three inde-
pendent experiments, mean±SD.
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stimulatory effect
We next examined the binding domains of RIG-I to
aptamer CL9. For this purpose, each mutant form of
RIG-I was overexpressed in HEK293 cells, and
32P-labeled CL9 binding to the immunoprecipitated
RIG-I proteins was measured (Figure 5A and B). CL9
was present in the immunoprecipitated Flag-RIG-I
complex, but this binding was signiﬁcantly diminished in
the immunocomplex with Flag-RD or Flag-CARD. In
contrast, CL9 was found in the immunocomplex with
Flag-Helicase+RD, which contains a helicase domain as
well as a carboxyl-terminal RD domain. Direct binding
A
5’- GGGAGAGCGGAAGCGUGCUGGG  CCACCAUCCGUAACUAGCUAAUACUUGUUAUCUUUUUAUUUU  CAUAACCCAGAGGUCGAUGGAUCCCCCC -3’ 
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Figure 4. Unique sequence features of CL9 for RIG-I activation. (A) Sequence of the CL9 mutants used in this study. 3ct, deletion mutants in the
30-common tail region; 5ct, a deletion mutant in the 50-common tail region; pU, mutants with point mutations in the polyU motifs; pA, pC, pG,
mutants with poly A- C- or Gs in the polyU motif, respectively; sl, a mutant with substitutions in the predicted internal stem-loop; ipU, a mutant
with internal polyU motif. (B and C) Effect of various CL9 mutants on IFNb production. HepG2 cells were stimulated with 75pmol of the indicated
CL9 mutants for 4h, and IFNb mRNA was measured by qRT-PCR. Mock, Lipofectamine alone. Lib., library control. (D and E) Binding of CL9
mutants to the puriﬁed RIG-I protein, in vitro. The
32P-end labeled-aptamers bound to RIG-I protein in vitro were quantitated using LSA method.
(F) CL9 was prepared by in vitro transcription using 20-F-UTP/CTP (20-F) or 20-OH-UTP/CTP (20-OH). Signaling activity was measured by
luciferase assay in the pPRD-III-I-luc transfected HepG2 cells. Representative data of three independent experiments are shown, mean±SD.
A Merge IRF3 DAPI
M
o
c
k
L
i
b
r
a
r
y
C
L
9
P
o
l
y
I
:
C
B
0
10
15
5
20
25
R
A
N
T
E
S
 
(
p
g
/
m
l
)
0
100
150
50
200
250
300
N.D
* *
C
0
200
300
100
400
500
0
10
25
5
0
100
300
200
D
PRDIII-I ISRE NFκB
0
40
80
60
20
0
0.8
1.2
0.4
0
4
8
6
2
10
12
mock library CL9 mock library CL9 mock library CL9
mock library CL9 mock library CL9 mocklibrary CL9
mock library CL9
T
N
F
α
 
(
p
g
/
m
l
) 400
20
15
30 600
R
e
l
.
 
a
c
t
i
v
i
t
y
 
(
f
o
l
d
)
I
F
N
β
 
m
R
N
A
 
R
A
N
T
E
S
 
m
R
N
A
(
X
1
0
 
 
)
T
N
F
α
 
m
R
N
A
3
Figure 3. RIG-I aptamer activates signaling pathways for IFNb produciton. (A) Nuclear translocation of IRF3 by RIG-I aptamer. The stimulated
cells were stained with an IRF3 antibody (green) and Hoechst 33258 (nucleus). (B) HepG2 cells were transfected with PRD-III-I-Luc, NFkB-Luc, or
ISRE-Luc reporter, and stimulated with 75pmol of AP-treated aptamers for 8h. (C and D) HepG2 cells were stimulated with AP-treated CL9
(75pmol) for 12h. The expression of IFNb, RANTES, and TNFa gene was measured by qRT-PCR in mRNA level (C), and by ELISA assay in
protein level (D). Data from three independent experiments, mean±SD.
Nucleic Acids Research,2012, Vol.40, No. 6 2729between CL9 and mutant forms of RIG-I was separately
conﬁrmed using bacterially puriﬁed recombinant proteins
in vitro (Figure 5C).
Although our data indicate that CL9 binds directly to
the C-terminal RD and helicase domain of RIG-I, aptamer
binding itself was not sufﬁcient to activate RIG-I-mediated
signaling activity, as none of the RIG-I mutants was able
to transmit aptamer-speciﬁc signaling activity (Figure 5D).
These data indicate that CL9 requires an intact form of
RIG-I to elicit its signaling activity. Because CL9 functions
in a 50-triphosphate-independent manner, we wondered
whether providing a 50-triphosphate-dsRNA moiety in
trans can further enhance signaling activity of CL9. To
test this idea, the signaling activity of CL9 in the absence
or presence of 50-triphosphate-dsRNA was examined in
the RIG-I overexpressed Huh7 cells (Figure 5E).
However, no additive effect was observed, indicating that
CL9 binding was sufﬁcient to provide conformational
change of RIG-I for full activity.
RIG-I speciﬁc RNA aptamer CL9 efﬁciently blocks viral
replication
RIG-I-dependent activation of IFNb expression is a key
step to trigger antiviral responses against foreign RNA
viruses, such as inﬂuenza virus, NDV, VSV and HCV
(20). Therefore, we evaluated whether RIG-I aptamer
has the potential to inhibit the replication of infected
RNA viruses. To do this, HepG2 cells were infected
with either NDV-GFP, or VSV-GFP, which both
contain a gene coding Green Fluorescent Protein (GFP)
in the viral genome (38) (Supplementary Figure S6). To
evaluate its therapeutic potential, cells were treated with
CL9 3h after virus infection, and viral replication was
assayed 3 or 9h later (Figure 6A). In contrast to the
RNA library pools used as negative control, CL9 treat-
ment efﬁciently blocked replication of NDV and VSV
(Figure 6B and C). Similar effect on the repression of in-
ﬂuenza A (PR8 strain)-GFP replication was also
demonstrated in the cells treated with CL9 (Figure 6D).
We then examined whether pre-treating cells with CL9
prior to viral infection had any preventative effects
(Figure 7A). NDV replication was almost completely
blocked when cells were treated with CL9 6h before in-
fection, visualized by ﬂuorescence of GFP (Figure 7B
and C) or PCR with virus speciﬁc primers (Figure 7D).
Efﬁcient induction of IFNb mRNA by CL9 was separ-
ately veriﬁed (Figure 7E). These results suggest that
RIG-I aptamer has strong potential to inhibit viral repli-
cation, via activation of RIG-I and IFNb production.
DISCUSSION
RIG-I is a DExH/D RNA helicase that senses intracellu-
lar non-self RNA structures derived from infected RNA
viruses. In this article, we report the identiﬁcation of
RIG-I-speciﬁc RNA aptamers with anti-viral potential.
The selected RIG-I aptamer behaves as a strong agonist
for RIG-I, as determined by its tendency to activate
RIG-I-mediated signaling pathways and its dependence
on the expression of RIG-I. As a result, RIG-I aptamer
Figure 5. CL9 binds to the RD-containing Helicase domain of RIG-I.
(A) Schematic diagram of the RIG-I mutants used in this study. (B)
Left, AP-treated
32P-CL9 was mixed with the indicated proteins that
were over-expressed in HEK293 cells. Right, The expression level of the
transfected protein was measured by western blot assay. (C) Left,
Wild-type or mutant forms of RIG-I protein were puriﬁed from
bacteria and incubated with AP-treated
32P-CL9 in vitro. Right, The
expression of each protein was measured by Coomassie blue staining (D)
Left, Huh7 cells were transfected with various RIG-I mutant plasmids as
indicated, along with PRD-III-I-Luc and pRL-CMV, and luciferase
activity was assayed after stimulation for 6h. Right, Ectopic expression
of RIG-I mutants was measured using an anti-Flag antibody. (E) Similar
to (D), except cells were stimulated with 50-triphosphate-dsRNA
(100pmol) and/or AP-treated CL9 (100pmol) for 6h. Data from more
than three independent experiments, mean±SD.
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Figure 6. Post-treatment of CL9 blocks viral replication. (A)
Experimental scheme: HepG2 cells were infected with virus for 3h
before aptamer (75pmol) treatment and incubated for an additional
3 or 9h before the assay. Presence of the viral fragment speciﬁc for
NDV (B) or VSV (C) was analyzed by qRT-PCR. Mean (±SD) values
of three independent samples are shown (Student t-test, *P<0.05). (D)
A549 cells were infected with Inﬂuenza A (H1N1, PR8)-GFP virus for
3h before aptamer treatment and incubated for additional 9h. The
fraction of virus-infected cells was measured by FACS analysis (gray:
mock-infection, black: virus-infection).
2730 Nucleic Acids Research, 2012,Vol.40, No. 6efﬁciently blocked replication of RNA virus in infected
cells, suggesting it has a strong potential for therapeutic
applications.
Originally identiﬁed as a cytosolic receptor for non-self
RNA, RIG-I monitors unique RNA structures in the
cytoplasm. It binds dsRNA with 50-triphosphate moiety
via carboxyl-terminal RD domain of RIG-I (14,39,40).
Double-stranded RNA of intermediate length (between
300 and 2000bp) and blunt-ended short dsRNA
(23 30bp) are also known to be recognized by RIG-I,
although they lack 50-triphosphate moiety (12,41,42).
RIG-I tends to have a preference for dsRNA, as ssRNA
with 50-triphosphate moiety fails to activate RIG-I (30). In
contrast to the conventional ligands of RIG-I, the selected
RIG-I aptamers seem to utilize distinct binding strategies:
the 50-triphosphate moiety of the aptamer was not
required for its binding to RIG-I, yet the helicase and
C-terminal RD domains of RIG-I were essential for its
binding. Because it has been reported that self-templated
‘copy-back’ activity of T7 RNA polymerase generates
double-stranded RNA (34), we wondered whether
in vitro transcribed RIG-I aptamer forms a dsRNA struc-
ture. When we evaluated the size of the transcribed RIG-I
on a denaturing polyacrylamide gel, in vitro transcribed
RIG-I aptamer migrated to the position that matches
the size of the single-stranded RIG-I aptamer
(Supplementary Figure S7). In addition, its stimulating
potential of RIG-I-mediated signaling activity was
strictly dependent on the polyU motifs and its position
within aptamer (Figure 4), rather than its physical
binding to RIG-I, suggesting that the unique feature
derived from the selected aptamer plays an important
role in the activation of the RIG-I. It is noteworthy to
mention that unanchored K63-poly-Ub chains have been
reported to act as a potent ligand of RIG-I, thereby
suggesting that there are another class of RIG-I ligand
that functions non-conventional manner (43).
In this study, we showed that RIG-I aptamer binds to
the RD-containing helicase domain of RIG-I and stimu-
lates RIG-I-dependent signal in a 50-triphosphate-
RNA-independent manner. Speciﬁcally, the polyU motif
found near the 30 side of RIG-I aptamer, CL9, was essen-
tial for the activation of the RIG-I. This polyU motif is
somewhat reminiscent of the polyU/UC in the RNA of
replicating HCV, which has been identiﬁed as a strong
ligand for RIG-I (44,45). However, a couple of differences
exist between these two motifs. First, polyAG/A showed
comparable activity to polyU/UC of HCV genome in the
production of IFNb, but the replacement of U with polyA
of CL9 almost completely blocked IFNb expression.
Second, the RIG-I activating signal of the polyU/UC in
the HCV genome was diminished when 20-F-uridine was
used instead of 20-OH-uridine. However, in vitro-
synthesized CL9 with 20-F-uridine and 20-F-cytosine ex-
hibited much stronger activity over transcripts generated
with 20-OH-uridine and 20-OH-cytosine. It is noteworthy
to mention that RNA aptamers synthesized with
20-F-uridine and 20-F-cytosine exhibits increased RNA
stability compared to 20-OH-uridine and 20-OH-cytosine,
due to the resistance to nuclease digestion (46). And
ﬁnally, polyU/UC of HCV is reported to lose its activity
after PAGE puriﬁcation (44,45), but in vitro-
synthesized CL9 keeps its activity after the same puriﬁca-
tion procedure. In all, these data indicate that RIG-I ac-
tivation by RIG-I aptamer is quite distinct that of
the polyU/UC sequence derived from the HCV RNA
genome.
We propose that RIG-I aptamers can be potential tools
based on their ability to enhance IFNb production and
block viral replication. Due to the immune-cell-restricted
expression patterns of Toll-like receptor (TLR) family
members and their localization on the surface
membrane, reagents that target these proteins have been
actively screened for the treatment of viral infection or
inﬂammation-related diseases (47,48). In contrast, RIG-I
is mainly expressed in non-immune cells and localizes in
the cytoplasm, presenting technical difﬁculties associated
with intracellular delivery of the targeting agents.
Furthermore, RIG-I is mainly expressed in ﬁbroblasts,
epithelial cells, hepatocytes, and conventional dendritic
cells (cDCs) (20), all of which express very low levels of
TLRs, suggesting that reagents that target TLRs may not
be ideal for systemic application. Instead, local applica-
tion of RIG-I aptamers to the infected sites may present
an attractive alternative. For example, local injection of
RIG-I aptamers in olfactory or airway epithelial cells may
be effective for treatment of human metapneumovirus
(HMPV) or respiratory syncytial virus (RSV) infection,
which are both recognized by RIG-I and are known to
cause bronchiolitis and even pneumonia (15,49). In
summary, we report RIG-I RNA aptamers have a
strong tendency to stimulate IFNb expression and block
viral replication. Further studies to increase the efﬁcacy
and stability of RIG-I aptamers, as well as the develop-
ment of cellular delivery tools, are necessary.
Figure 7. Pre-treatment of CL9 inhibited viral replication. (A)
Experimental scheme: Prior to virus infection, HepG2 cells were
pre-treated with 75pmol of aptamers for 6h. Viral replication was
assayed after 12h of treatment by immunoblot against anti-GFP (B)
or GFP ﬂuorescence (C). (D and E) Same experimental scheme as (A),
except RNA for NDV (D) and IFNb (E) were analyzed: Student t-test,
**P<0.005, *P<0.05, relative to the mock-treated sample. Data from
more than three independent experiments.
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